Also known as: ZP8396
Petrelintide is a long-acting amylin analog from Zealand Pharma, partnered with Roche, dosed once weekly by subcutaneous injection. It delivered double-digit weight loss with placebo-like tolerability in the Phase 2 ZUPREME-1 trial, and moved into Phase 3 for chronic weight management in the second half of 2026.
Petrelintide pursues weight loss through amylin receptor agonism rather than the GLP-1 or dual GIP/GLP-1 mechanisms behind every high-efficacy weight-management drug currently approved. The headline claim from Phase 2 is not raw efficacy but tolerability: double-digit weight reduction with a side-effect profile the company describes as placebo-like, which if it holds in Phase 3 would matter, since GI intolerance drives much of the real-world discontinuation seen with incretin drugs.
It is engineered for chemical and physical stability with no fibrillation near neutral pH — a practical property that allows co-formulation with other peptides, and the reason it is being positioned as a combination backbone as well as a monotherapy. Not yet approved.
Amylin is co-secreted with insulin from pancreatic beta cells in response to nutrients. Agonising its receptor slows gastric emptying and promotes satiety, and is understood to restore sensitivity to leptin — producing fullness earlier in a meal through a pathway independent of GLP-1.
Acylation drives albumin binding, extending the circulating half-life enough to support once-weekly subcutaneous dosing.
Investigational and not commercially available. The interesting claim here is tolerability rather than peak efficacy — GI side effects drive much real-world discontinuation of incretin drugs, so an amylin agonist that avoids them could matter even at comparable weight loss.
As with other weight-management agents, weight regain on discontinuation is expected but not yet characterised for this compound.
Investigational — Phase 3 only, not approved. No verified consumer source exists.
Investigational, Phase 3 (initiated H2 2026) for chronic weight management. The full amino acid sequence has not been publicly disclosed; it is described as a 36-residue acylated analog of human amylin. Molecular weight here is derived from the published molecular formula.
Ask anything about Petrelintide — mechanisms, dosing protocols, interactions, or research comparisons.
Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (…
Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. It pr…
AOD-9604 is a modified fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine residue…
Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. It mimics the satiety and gastric-empty…